Intrinsic resistance mechanisms to mutant KRAS specific inhibitor in KRAS mutated colorectal cancer

被引：0
|
作者：
Maruyama, Kohei [1 ,2 ]
Suzuki, Mai [1 ,2 ]
Ohhara, Tomoko [1 ]
Nagayama, Satoshi [3 ]
Fujita, Naoya [4 ]
Katayama, Ryohei [1 ,2 ]
机构：
[1] JFCR, Div Exp Chemother, Canc Chemother Ctr, Tokyo, Japan
[2] Univ Tokyo, Dept CBMS, Grad Sch Front Sci, Tokyo, Japan
[3] JFCR, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
[4] JFCR, Canc Chemother Ctr, Tokyo, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-2032
引用
收藏
页码：783 / 783
页数：1
相关论文
共 50 条
  • [31] Determining if osteopontin is an immune checkpoint of KRAS mutant colorectal cancer
    Nowlan, B.
    Borowsky, J.
    Dumenil, T.
    Tria, S.
    Wright, J.
    Fennell, L.
    Bond, C.
    McKeone, D.
    Hartel, G.
    Woods, S.
    Leggett, B.
    Whitehall, V.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 24 - 24
  • [32] Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
    Knickelbein, Kyle
    Zhang, Lin
    GENES & DISEASES, 2015, 2 (01) : 4 - 12
  • [33] Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer
    Maitra, Radhashree
    Thavornwatanayong, Thongthai
    Venkatesh, Madhu Kumar
    Chandy, Carol
    Vachss, Dov
    Augustine, Titto
    Guzik, Hillary
    Koba, Wade
    Liu, Qiang
    Goel, Sanjay
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (22)
  • [34] Chromatin condensation in KRAS-mutant lung cancer as a therapeutic target: challenging the paradigm of associating KRAS mutation with EGFR inhibitor resistance
    Wang, Meng
    Kern, Ashley M.
    Huelskoetter, Marieke
    Greninger, Patricia
    Singh, Anurag
    Pan, Yunfeng
    Chowdhury, Dipanjan
    Krause, Mechthild
    Baumann, Michael
    Benes, Cyril H.
    Efstathiou, Jason A.
    Settleman, Jeff
    Willers, Henning
    CANCER RESEARCH, 2014, 74 (19)
  • [35] KRAS and Cancer Stem Cells in APC-Mutant Colorectal Cancer
    Fearon, Eric R.
    Wicha, Max S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [36] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
  • [37] KRAS Mutant Lung Cancer
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S92 - S93
  • [38] Non-engineered T cells with specific anticancer effects in KRAS-mutated colorectal cancer
    Lim, Sunki
    Gho, Yujeong
    Kim, Seoyoung
    Kim, Min Ki
    Park, Jong Seob
    Lee, Wang Jun
    Lee, Young-Kwan
    Moon, Hyoun Jong
    CANCER RESEARCH, 2023, 83 (07)
  • [39] YY1 as a mediator to enhance the resistance of KRAS mutant colorectal cancer cells to cetuximab
    Ma, Yi
    Hu, Yuli
    Lin, Yi
    Wang, Congying
    Lv, Yujie
    Chen, Wei
    JOURNAL OF GENETICS, 2024, 104 (01)
  • [40] Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
    Ke Xu
    Dongkyoo Park
    Andrew T. Magis
    Jun Zhang
    Wei Zhou
    Gabriel L. Sica
    Suresh S. Ramalingam
    Walter J. Curran
    Xingming Deng
    Molecular Cancer, 18
12345